DR. CATHERINE JOHNSON O.D.
Prescription History 1003225921
Optometrist in Denham Springs, LA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CATHERINE JOHNSON O.D., an active Optometrist specialist practicing in Denham Springs, LA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 200 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 59 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other LA PrescribersVs. LA Avg |
|---|---|---|---|
| Latanoprost | 59 | $3.70▼ below LA avg | ▼ Less than typical |
About Latanoprost: Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). Show more ▾ It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness. A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA. In 2024, this provider wrote 59 Medicare prescriptions for Latanoprost, about a third of the volume of the typical Louisiana prescriber of this medication (182.4). Medicare paid an average of $3.70 per fill, versus $9.96 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 83.3 30-Day Fills standardized to 30-day supplies 2,302 Days of Medication total across all patients in 2024 | |||
| LumiganBimatoprost | 44 | $310.33▼ below LA avg | ≈ Typical |
About Lumigan: Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Show more ▾ Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure. A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. In 2024, this provider wrote 44 Medicare prescriptions for Lumigan, about 77% of the volume of the typical Louisiana prescriber of this medication (57). Medicare paid an average of $310.33 per fill, versus $411.51 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 49.3 30-Day Fills standardized to 30-day supplies 1,374 Days of Medication total across all patients in 2024 | |||
| RestasisCyclosporine | 29 | $1,227.46 | ▼ Less than typical |
About Restasis: Cyclosporine eye drops are used to treat a certain type of dry eyes. Show more ▾ They work by increasing the amount of tears you make. A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). In 2024, this provider wrote 29 Medicare prescriptions for Restasis, about half the volume of the typical Louisiana prescriber of this medication (53.6). Medicare paid an average of $1,227.46 per fill, versus $904.92 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 57 30-Day Fills standardized to 30-day supplies 1,710 Days of Medication total across all patients in 2024 | |||
| Prednisolone Acetate | 21 | $32.18▼ below LA avg | ▼ Less than typical |
About Prednisolone Acetate: This medication is used to treat certain eye conditions due to inflammation or injury. Show more ▾ Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids. A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. In 2024, this provider wrote 21 Medicare prescriptions for Prednisolone Acetate, about 17% of the volume of the typical Louisiana prescriber of this medication (121). Medicare paid an average of $32.18 per fill, versus $41.96 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 21.8 30-Day Fills standardized to 30-day supplies 464 Days of Medication total across all patients in 2024 | |||
| TyrvayaVarenicline Tartrate | 20 | $645.27▼ below LA avg | ≈ Typical |
About Tyrvaya: Varenicline is used to treat dry eyes. Show more ▾ It works by increasing the amount of tears you make. A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION. In 2024, this provider wrote 20 Medicare prescriptions for Tyrvaya, about 81% of the volume of the typical Louisiana prescriber of this medication (24.7). Medicare paid an average of $645.27 per fill, versus $743.51 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 20 30-Day Fills standardized to 30-day supplies 550 Days of Medication total across all patients in 2024 | |||
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 15 | $14.43 | ▼ Less than typical |
About Neomycin-Polymyxin-Dexameth: This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. Show more ▾ This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness. In 2024, this provider wrote 15 Medicare prescriptions for Neomycin-Polymyxin-Dexameth, about a third of the volume of the typical Louisiana prescriber of this medication (50.3). Medicare paid an average of $14.43 per fill, versus $12.54 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 15.2 30-Day Fills standardized to 30-day supplies 299 Days of Medication total across all patients in 2024 | |||
| MieboPerfluorohexyloctane/Pf | 12 | $723.86▼ below LA avg | ▼ Less than typical |
About Miebo: This medication is used to relieve dry, irritated eyes. Show more ▾ Perfluorohexyloctane works by keeping your tears from drying up. This keeps the eye moist, helps protect the eye from injury and infection, and decreases symptoms of dry eyes such as burning, itching, and feeling as if something is in the eye. Used for removing silicone oil from the surface of silicone intraocular lenses; MF is C14F13H17. In 2024, this provider wrote 12 Medicare prescriptions for Miebo, about half the volume of the typical Louisiana prescriber of this medication (20.5). Medicare paid an average of $723.86 per fill, versus $835.42 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average LA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the LA average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. CATHERINE JOHNSON O.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Optometrist prescribing approach at this Denham Springs, LA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among LA prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
